Breast cancer vaccine reduces tumours in mice

Scientists develop vaccine that attacks breast cancer in mice — Implications for the treatment of ovarian, colorectal and pancreatic cancer, as well – Researchers have developed a vaccine that dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases-including those that are resistant to common treatments.

New 3 drug combination for multiple myeloma patients

Multiple myeloma patients experience high response rate with new 3-drug combination – A new three-drug combination has shown in a phase 1/2 clinical trial that it is a “highly effective regimen” in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

Thalidomide does not improve survival in lung cancer

JNCI news brief: Thalidomide does not improve survival in small cell lung cancer – Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, revealed by researchers.

New cancer gene UTX identified

Getting down to cancer basics — Cancer mutations in the heart of gene regulation. – Researchers have identified a new cancer gene – one that is common to many cancers and affects the most basic regulation of our genes.

Melanoma skin cancer linked to mental stress

Stress may hasten the growth of melanoma tumors but common beta-blocker medications might slow that progress. – For patients with a particularly aggressive form of skin cancer malignant melanoma stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.

Cancer drug bortezomib effectively treats transplant rejections

Cancer drug bortezomib ? used to treat multiple myeloma – effectively treats organ transplant rejections. – University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.

Novel anti-cancer strategy moves to clinic

Emory University researchers have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells. – Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells.

Do NOT follow this link or you will be banned from the site!